Linked Life Data

2734758

Source:http://linkedlifedata.com/resource/pubmed/id/2734758

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1989-7-20
pubmed:abstractText
About 10% of cancer patients develop hypercalcemia. The mechanisms behind the development of hypercalcemia are complex, but the most important facts seems to be increased osteoclastic bone resorption. Several cellular mediators play a part in creating and sustaining hypercalcemia. The article discusses these mechanisms, and reviews the principles of treatment. Emphasis is placed on rehydration and on inhibition of bone resorption. The use of diphosphonates (bisphosphonates), a group of potent osteoclast inhibitors, is discussed in some detail.
pubmed:language
nor
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0029-2001
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
109
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1293-6
pubmed:dateRevised
2008-7-16
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
[Hypercalcemia in malignant diseases. Physiopathology and treatment].
pubmed:publicationType
Journal Article, English Abstract